OncoMatch/Clinical Trials/NCT06001151
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Is NCT06001151 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cadonilimab and Pemetrexed for carcinoma, non-small-cell lung.
Treatment: Cadonilimab · Pemetrexed · Carboplatin — This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) TPS <1% (TPS <1%)
PD-L1 TPS<1%
Required: EGFR wild-type
Without EGFR-sensitive mutation (19Exon del/21Exon L858R)
Required: ALK wild-type
Without...ALK...gene rearrangement or fusion
Required: ROS1 wild-type
Without...ROS1 gene rearrangement or fusion
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Has adequate organ function
Kidney function
Has adequate organ function
Liver function
Has adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify